What are the potential therapeutic benefits and risks of tetrahydrocannabinol (THC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

THC Has Both Significant Therapeutic Benefits and Serious Risks—The Balance Depends Critically on Patient Population, Dose, and Clinical Context

For most patients, the risks of THC outweigh potential benefits, particularly for adolescents, young adults, pregnant individuals, and those with psychiatric conditions, but FDA-approved synthetic THC formulations have established therapeutic roles in specific clinical scenarios. 1

Established Therapeutic Benefits

FDA-Approved Indications

The clearest evidence for THC's therapeutic value comes from FDA-approved synthetic formulations:

  • Dronabinol (synthetic THC): Approved for chemotherapy-induced nausea/vomiting and AIDS-related anorexia/weight loss 1
  • Nabilone (synthetic cannabinoid): FDA-approved antiemetic 1
  • Therapeutic reference ranges: For dronabinol, 5-15 ng/mL THC appears effective for chemotherapy-induced nausea/vomiting 2

Pain Management—Mixed Evidence

The evidence for chronic pain is contradictory and has weakened over time:

  • A 2017 National Academy of Medicine review concluded "substantial evidence" for chronic pain effectiveness 1
  • However, a more recent 2022 meta-analysis was "more circumspect," finding only "short-term improvements in chronic pain" with increased risk for dizziness and sedation 1
  • For vaporized/smoked medical cannabis, therapeutic concentrations of 15-30 ng/mL THC showed pain reduction in diabetic peripheral neuropathy 2

Clinical interpretation: The evidence has become less favorable over time, suggesting initial enthusiasm may have been premature.

Serious and Well-Documented Risks

High-Risk Populations—Absolute Contraindications

Adolescents and Young Adults 1, 3:

  • Neuropsychological and neurodevelopmental decline
  • 2-fold to 11-fold increased risk of psychosis with regular high-THC use 3
  • Elevated risk for psychotic disorders in adulthood
  • Higher risk for depression and suicidal ideation
  • Increased risk of cannabis use disorder (CUD)—optimal threshold is only 6.04 units/week (approximately 30 mg THC weekly) 4

Pregnant and Breastfeeding Individuals 1:

  • Negative effects on fetal brain development
  • Increased risk for premature birth
  • U.S. Surgeon General and FDA explicitly advise complete avoidance 1

Patients with Psychiatric Disorders 3:

  • Worsening mania and function in bipolar disorder
  • Increased psychotic symptoms in psychotic spectrum disorders
  • Increased self-harm risk in mood disorders
  • Low-certainty evidence shows THC-predominant cannabis does NOT improve PTSD symptoms 3

Cardiovascular Risks

  • Myocardial infarction and stroke association 1
  • In older adults: sedation, obtundation, myocardial ischemia or infarction 1
  • Increased risk for new-onset arrhythmia (180-day risk in Danish chronic pain patients) 1

Respiratory Risks

  • Chronic bronchitis and COPD association with smoking 1
  • Acute lung injury from THC-containing e-cigarettes with vitamin E acetate—CDC/FDA recommend avoiding THC vaping products, especially from informal sources 1

Cannabis Use Disorder

  • Among people with past-year cannabis use, approximately 3 in 10 develop CUD 3
  • About half of those with CUD have moderate/severe disease with negative social and employment outcomes 3
  • THC has "high potential for misuse" per Substance Abuse and Mental Health Services Administration 1
  • Withdrawal symptoms: irritability, insomnia, headaches 1

Pediatric Exposures

  • Dramatic increase: 207 cases in 2017 to 3,054 cases in 2021 1
  • Children ingesting >30 mg THC: 28% developed severe symptoms, 66% had CNS depression, 17% had respiratory depression 5

Dose-Response Relationships

Risk Thresholds for CUD 4:

  • Adults: 8.26 standard THC units/week (41.3 mg THC) for any CUD risk; 13.44 units/week (67.2 mg) for moderate/severe CUD
  • Adolescents: 6.04 units/week (30.2 mg) for any CUD risk; 6.45 units/week (32.25 mg) for moderate/severe CUD

Critical caveat: These thresholds are remarkably low—adolescents approach high risk with consumption equivalent to just 6 mg THC daily.

Potency Concerns

  • Average THC concentration nearly doubled from 9% (2008) to 17% (2017) 1
  • Cannabis concentrates may contain up to 70% THC 1
  • High-dose THC associated with psychosis 1

Clinical Algorithm for Decision-Making

Step 1: Screen for Absolute Contraindications

Do NOT recommend THC if patient is:

  • Adolescent or young adult (age <25)
  • Pregnant or breastfeeding
  • Has bipolar disorder, psychotic disorder, or mood disorder with self-harm risk
  • Has history of substance use disorder

Step 2: Consider FDA-Approved Alternatives First

For appropriate indications:

  • Chemotherapy-induced nausea/vomiting: Use dronabinol (2.5 mg PO TID, titrate to 10 mg TID-QID) or nabilone (1 mg PO BID, titrate to 2 mg QID) as salvage antiemetics 6
  • AIDS-related anorexia: Use dronabinol 1

Step 3: Counsel on Risks vs. Benefits

If considering medical cannabis for chronic pain in appropriate patients:

  • Evidence shows only modest short-term benefit with significant adverse effects 1
  • Start with lowest possible dose (therapeutic effects may occur at 7-10 ng/mL for some conditions) 2
  • "Start low, go slow" approach is mandatory 6
  • Monitor for dizziness, sedation, dysphoria, impaired driving ability

Step 4: Monitor for Adverse Effects

  • Assess for euphoria, drowsiness, dizziness, vertigo, hallucinations 6
  • Screen regularly for CUD symptoms
  • Monitor cardiovascular status in older adults
  • Warn about delayed onset with oral products (30 minutes to 2 hours) and risk of "stacking doses" 6

Critical Pitfalls to Avoid

  1. Assuming "natural" means safe: Cannabis products have substantial risks, particularly with increasing THC potency 1

  2. Ignoring drug interactions: THC inhibits multiple CYP450 enzymes; potential interactions with warfarin and other medications 6, 7

  3. Underestimating addiction potential: 30% of past-year users develop CUD 3

  4. Recommending for psychiatric conditions: Evidence does not support use for PTSD, anxiety, depression, or ADHD, and may worsen outcomes 3

  5. Failing to warn about driving impairment: THC affects reaction time and coordination 1

  6. Not counseling about edible product risks: Delayed onset leads to overdosing; products resemble candy, creating pediatric exposure risk 1

Bottom Line

The 2024 American College of Physicians guideline represents the most authoritative current evidence 1. While FDA-approved synthetic THC formulations have narrow, well-defined therapeutic roles, the broader use of medical cannabis or THC products carries substantial risks that often outweigh uncertain benefits. The evidence base has become less favorable over time, particularly for chronic pain. For vulnerable populations—adolescents, pregnant individuals, and those with psychiatric disorders—the risks are unequivocal and severe, including psychosis, developmental harm, and addiction. When THC is considered appropriate, use only FDA-approved formulations at the lowest effective doses with careful monitoring.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.